The Research On Curative Effect And Influence Of Transforming Growth Factor-β₁ Of Chronic Obstructive Pulmonary Disease With Deficiency Of Both Lung And Spleen In Stable Phase By Feikangkeli

Objective:To observe the curative effect and influence of Transforming Growth Factor-β₁(TGF-β₁) of chronic obstructive pulmonary disease(COPD) with deficiency of both lung and spleen in stable phase by Feikangkeli(FKKL) from clinical and experimental study.Method:1.Clinical Research:60 patients conformed to the research conditions were randomly divided into the treating group or control group.The treating group was treated with FKKL combined with slow-release aminophylline,and the control group was treated only with slow-release aminophylline.The course of treatment was three months.To observe the variance of zhenhou,pulmonary function,TGF-β₁.2.Experimental Study:40 SD rats were randomly divided into four groups, including normal control group,COPD model group,high-dose FKKL group, low-dose FKKL group,each group with 10.To Set up the COPD deficiency of both lung and spleen animal models with the methods of cigarettes smoked,repeated infusion of lipopolysaccharide in the airway and pour the Senna-water into the rats' stomach.When the therapy was finished,to Observe the variance of lung tissue pathology,the rats' small airway wall thickness,the excretory rate of D-xylose,and the TGF-β₁ protein expression in bronchus and lung tissue.Result: 1.Clinical Research1.1 The zhenghou of the treating group had significant difference(P＜0.05) post-treatment comparing with pre-treatment.There was not significant difference comparing with pre-treatment except for the symptoms such as cough,expectoration,polypnea,gasp in the control group.Post-treatment, except for the symptom of cough,polypnea,gasp all other symptoms in the treatmenting group had significant difference to the control group (P＜0.05).The total effective rate of the treating group and the control group were 93.10%and 68.97%respectively,the treating group was more higher (P＜0.05).1.2 Pulmonary function test:Post-treatment comparing with pre-treatment,the index of FEV₁,FVC,FEV₁%and FEV₁/FVC in both groups had significant improvement(P＜0.05).But these data of pulmonary function had no significant difference between the two groups after three-month' therapy.1.3 Comparing post-treatment with pre-treatment,the level of the TGF-β₁ protein expression descended significantly in the treating group(P＜0.05), however,the control group had no.2.Experimental Study2.1 The changes in emphysema in the animal model were similar to those in COPD patients.Both groups of FKKL lessen apparently than the model group about the changes in emphysema.2.2 Among the four groups,the rats' small airway wall thickness had significant difference(P＜0.05).The small airway wall thickness in the high-dose FKKL group and low-dose FKKL group was smaller than the model group.2.3 The excretory rate of D-xylose in the model group was obviously lower than the normal group(P＜0.05),prompting that it was successful to establish the COPD rat model.Compared with the model group,the excretory rate of D-xylose increased significantly(P＜0.05),in both the high-dose FKKL group and low-dose FKKL group.But there wasn't significant difference between the two groups.2.4 Compared with the normal group,the TGF-β₁ protein expression of other groups' was increased significantly(P＜0.05).The TGF-β₁ protein expression of high-ose and low-dose FKKL groups' was apparent weaker than the model group's(P＜0.05).But both the high-dose and low-dose FKKL groups' TGF-β₁ protein expression had no significant difference. Conclusion:1.The results indicate that the treatment of FKKL combined with slow-release aminophylline can improve the patients' zhenhou.Meanwhile, FKKL can obviously reduce the level of TGF-β₁ protein expression.But in the improvement of pulmonary function,the two groups have no significant difference.2.The FKKL can improve the general conditions of COPD rat models,relieve the pathological form of emphysema,slow down COPD rats' small airway wall thickening,elevate the excretory rate of D-xylose,reduce the level of TGF-β₁ protein expression.Thus it reveal the mechanism of treatment of FKKL from the domain of cytokine.However,the role of this treatment have the relationship with drug concentration or not,need to be further studied.